Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05278052
Other study ID # 3445
Secondary ID CTRI/2020/04/024
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 20, 2020
Est. completion date April 20, 2028

Study information

Verified date April 2023
Source Tata Memorial Hospital
Contact Dr. Anil Tibdewal
Phone +91-22-24177000
Email aniltibdewal@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial


Description:

Standard of care maintenance therapy alone (standard arm) versus local consolidative radiation therapy and standard of care maintenance therapy (Experimental arm)


Recruitment information / eligibility

Status Recruiting
Enrollment 190
Est. completion date April 20, 2028
Est. primary completion date April 20, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: 1. Age > 18 years 2. Patients with ECOG performance status of 0-2 3. Patients with pathologically proven diagnosis of NSCLC 4. Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than or equal to 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible) 5. Patients who have received standard duration of systemic therapy (4 - 6 cycles) without progression of the disease 6. Patients suitable for definitive therapy to the primary disease 7. All the Oligometastases lesions should be radiologically visible and suitable for ablative doses of radiation in accordance with the dose fractionation regimens specified in the protocol. 8. Patients who have received ablative radiation therapy or surgery or RFA for metastatic sites at presentation or during systemic therapy will be eligible provided the total number of oligometastatic sites at the time of study entry (treated site included) is less than or equal to five. 9. Patients who have received palliative RT for symptomatic bony metastases or RFA will also be eligible provided the treated site is under control on imaging. If not controlled, could be eligible for study if further ablative doses of radiation can be delivered according to the treating physician. 10. Patients who underwent surgical decompression, or stabilization followed by palliative radiation therapy for bony metastases will be eligible in the study provided the treated site is under control on imaging and patient has less than 5 sites of metastases at the time of study entry. 11. Adequate end organ function CBC/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows: - Absolute neutrophil count (ANC) = 500 cells/mm3; - Platelets = 50,000 cells/mm3; - Hemoglobin = 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb = 8.0 g/dl is acceptable); 12. For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration; 13. Patients willing for written informed consent and must be willing to comply with the specified follow up schedule Exclusion Criteria: 1. Patients with progressive disease after initial standard systemic therapy 2. Patients with oncogene driver mutations 3. Patients with more than 5 sites of oligo metastases 4. Patients with metastatic lesion size of more than 5 cm 5. Patients with more than three metastatic lesion in one organ 6. Patients not suitable for definitive radiation therapy to primary disease 7. Patients not suitable for ablative radiation therapy to metastatic sites 8. Patients with malignant peritoneal disease 9. Patients with malignant pleural effusion 10. Leptomeningeal disease 11. Brain metastases in the brain stem 12. Clinical or radiological evidence of spinal cord compression or metastases within 2 mm of spinal cord on MRI 13. Severe, active co-morbidity defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months; - Transmural myocardial infarction within the last 6 months; - Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; 14. Patients with prior history of radiation therapy to thorax 15. Patients with previous history of malignancy within last 3 years from the date of diagnosis 16. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Local consolidative radiation therapy
Local consolidative radiation therapy (LCRT) to all oligo-metastatic sites in addition to primary disease site
Drug:
Standard maintenance therapy as decided by the treating medical oncologist
Standard maintenance therapy/Observation

Locations

Country Name City State
India Tata Memorial Hospital, Parel Mumbai Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Tata Memorial Hospital

Country where clinical trial is conducted

India, 

References & Publications (1)

Tibdewal A, Agarwal JP, Srinivasan S, Mummudi N, Noronha V, Prabhash K, Patil V, Purandare N, Janu A, Kannan S. Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1-5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. BMJ Open. 2021 Mar 16;11(3):e043628. doi: 10.1136/bmjopen-2020-043628. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) Overall survival is defined as the duration between the date of randomization to the date of death due to any cause or the date of last follow-up, whichever is earlier. Upto 2 years
Secondary Progression free survival (PFS ) Progression free survival is defined as the duration between the date of randomization to the date of first documented progression or death due to any cause or date of last follow-up, whichever is earlier. Upto 2 years
Secondary Local control rates of treated sites Local control rate will be defined as the absence of progressive disease at the treated sites Upto 2 years
Secondary New distant metastases Time to onset of new distant metastases Upto 2 years
Secondary Health Related QOL using the EORTC-QLQ-C30 questionnaire To evaluate patient reported outcomes between the two arms From randomization every 3 months till 2 years
Secondary Health Related QOL using the EORTC- LC13 questionnaire To evaluate patient reported outcomes between the two arms From randomization every 3 months till 2 years
Secondary Response rates To compare response rates between the two arms From randomization every 3 months upto 2 years
Secondary Radiotherapy related toxicity using CTC v5.0 (radiotherapy related acute and late toxicity) At baseline and at subsequent follow up till 2 years Upto 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Not yet recruiting NCT06373497 - Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography Early Phase 1
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Recruiting NCT05223803 - TERPS Trial for de Novo Oligometastic Prostate Cancer Phase 2
Recruiting NCT04617457 - Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Recruiting NCT05679427 - Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions N/A
Recruiting NCT05277844 - Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC Phase 2
Active, not recruiting NCT05951127 - Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC N/A
Active, not recruiting NCT05101824 - Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease N/A
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT04748042 - Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Phase 2
Recruiting NCT06122480 - Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma N/A
Not yet recruiting NCT05784428 - Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression N/A
Completed NCT04593381 - Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer N/A
Terminated NCT01345539 - Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation Phase 2
Recruiting NCT05846646 - Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Phase 2
Recruiting NCT04973007 - Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases Phase 4
Recruiting NCT06439888 - Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT05917431 - Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC Phase 2

External Links